Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 12th, 2026

LECO_Weekly-Healthcare-News_10-12-2026Download

Healthcare Weekly News and Deals – Oct 12th, 2026

  1. Clayton, Dubilier & Rice and McKesson (NYSE: MCK) have agreed to take infusion provider Option Care Health (NASD: OPCH) private in a $5.8 billion deal at $32.05 per share, with CD&R holding 51% and McKesson about 49%. Clayton, Dubilier & Rice and McKesson (MCK) will acquire Option Care Health (OPCH), the largest independent U.S. provider of home and alternate-site infusion services, for $32.05 per share, a 37% premium to its prior close, valuing the deal at $5.8 billion. McKesson plans to invest about $1.4 billion for its roughly 49% interest, and the agreement sets out a framework for McKesson to later buy CD&R’s stake. Option Care treats more than 308,000 patients a year across all 50 states and generated over $5.6 billion of 2025 net revenue. McKesson framed the investment around its specialty and complex-therapy strategy. Closing is expected in the first half of 2027. (Link)
  2. STERIS (NYSE: STE) has agreed to acquire Xodus Medical for $2.1 billion at closing, or about $1.8 billion net of expected tax benefits, plus an earnout of up to $150 million. Xodus was founded in the early 1990s and is based in New Kensington, Pennsylvania, outside Pittsburgh. It builds devices meant to keep patients and operating-room staff safer during surgery. The core product is the Pink Pad, a positioning system used to hold patients in place and reduce pressure injury. A later version combines that pad with underbody warming to address perioperative hypothermia. Hospitals buy the line as a consumable rather than as capital equipment. STERIS already sells infection-prevention products and surgical supplies, so the tuck-in adds a branded safety line. Xodus is expected to do about $245 million of revenue in 2026, with adjusted EBIT of about $135 million. STERIS plans to fund the purchase mainly with debt. Completion is aimed at December 31, 2026 and still needs regulatory sign-off. (Link)
  3. Viatris (NASDAQ: VTRS) has agreed to acquire Pacira BioSciences (NASDAQ: PCRX) for $36.50 a share in cash, or $1.65 billion. Pacira’s commercial book is built on two non-opioid pain drugs. EXPAREL is a liposomal bupivacaine injection used for local pain control after surgery. ZILRETTA is an extended-release steroid injected into the knee for osteoarthritis. The two products booked about $692 million in 2025, and Pacira reported full-year revenue of about $726 million. Both are already on the market, so this is a product acquisition rather than a pipeline bet. The cash price is a 45 percent premium to the prior close. Viatris, based in Pittsburgh, has been shifting from generics and established brands toward a smaller innovative-medicines franchise, and has an oral meloxicam under FDA review with a December 27 decision date. Generic erosion of EXPAREL is expected to begin in early 2030 under earlier patent settlements. Close is expected by the end of 2026. (Link)
  4. BDT & MSD Partners has agreed to acquire a majority stake in Sunrise Senior Living from the Public Sector Pension Investment Board (PSP Investments) in a deal reportedly valuing the operator above $1 billion, with Sunrise management owning the balance. Funds affiliated with BDT & MSD Partners signed a definitive agreement to buy Sunrise Senior Living from Canada’s PSP Investments, which first invested in 2014 and became sole owner in 2023. CEO Jack Callison Jr. and senior executives will invest significant personal capital alongside BDT & MSD’s majority position. Press reports cite a valuation above $1 billion. Sunrise operates more than 230 communities in North America, serving over 22,000 residents and has a pipeline of 50-plus communities with expected development costs of about $7.5 billion. (Link)
  5. Healthcare Services Group (NASD: HCSG) has acquired Mansfield, Massachusetts-based dining and hospitality manager NEXDINE Hospitality for $93.5 million upfront plus a performance-based earnout. Healthcare Services Group (HCSG), the Bensalem, Pennsylvania-based provider of housekeeping, laundry and dining services to healthcare facilities, acquired privately held NEXDINE Hospitality, announced on October 7, 2026, paying $93.5 million upfront in cash on hand, with additional consideration if NEXDINE meets certain performance targets. NEXDINE, a dining and hospitality service management company with a strong senior living presence, is expected to contribute more than $150 million of annual revenue, implying an upfront price of about 0.6x sales. It will operate as a wholly owned subsidiary under its own brand, led by founder and CEO David Lanci. HCSG framed the deal as an expansion into senior living and hospitality-driven care markets. (Link)
  6. Tiffin, Ohio-based Surgence Innovations has secured a $15 million investment from private funds advised by Ohio investor The O.H.I.O. Fund, spinning out as an independent company from Ohio distributor Concordance Healthcare Solutions. Surgence, a healthcare supply chain platform built on the Palantir (NASD: PLTR) Foundry operating system, announced the $15 million on October 6, 2026, with the capital establishing it as an independent corporation. It was incubated under Tiffin, Ohio-based Concordance Healthcare Solutions, an independent distributor with 15 distribution centers licensed in 48 states, which keeps a significant ownership stake and remains a strategic and commercial partner. The O.H.I.O. Fund invests exclusively alongside businesses that call Ohio home; partner Mike Venerable framed the deal as long-term capital supporting Ohio’s healthcare leadership. Proceeds will fund product development, customer growth, hiring and innovation across the healthcare supply chain. (Link)
  7. Standard BioTools (NASDAQ: LAB) has agreed to sell its Microfluidics business to ARCHIMED. The unit being carved out makes integrated fluidic circuits, small chips that run hundreds to thousands of reactions from a single sample. Research labs use them for genotyping, gene-expression work and library preparation ahead of next-generation sequencing. The technology came in through Fluidigm, the predecessor company, and has been cited in thousands of genomics papers. The buyer is a healthcare-only private equity firm founded in 2014 and based in Lyon, France. It invests in life-science tools, diagnostics and medtech on both sides of the Atlantic, and is taking the unit as a standalone business rather than folding it into an operating company. The Boston seller has been pruning a portfolio assembled through earlier combinations. Closing is expected in about 30 days. No price was given. (Link)
  8. Spectrum Equity has made a strategic growth investment in healthcare supply chain data provider Symmetric Health Solutions, the company’s first institutional capital. Spectrum Equity, a growth equity firm founded in 1994 that focuses on AI, software and data businesses, backed Symmetric in a deal announced on October 6, 2026; the size was not disclosed. Founded in 2018 by former Accenture supply chain consultants and Carnegie Mellon alumni, Symmetric reached profitability without outside capital and maintains a database of nearly 20 million healthcare items, each with up to 1,800 metadata attributes, used by more than 850 hospitals. Managing Director Michael Radonich said the company has become the system of record for supply data at several of the largest U.S. health systems. Proceeds fund go-to-market, customer success and new products, including a supply chain control tower. (Link)
  9. FFL Partners has made a growth investment in Nashville-based Ally Technical, the healthcare technology management company formerly known as Althea US. FFL Partners backed Ally Technical alongside the company’s rebrand, in a deal announced on October 6, 2026 with undisclosed terms. Ally Technical provides service, parts, board-level and depot repair, technical support and training for medical equipment from major manufacturers, built on deep expertise in contrast injectors, and supports a large installed base of aging devices across the U.S. FFL partner Karen Winterhof said providers are increasingly turning to independent service organizations for cost-efficient maintenance and parts. The investment came out of FFL’s SEED sector-exploration strategy, and the partners plan organic growth plus M&A, including expansion into new device modalities and under-penetrated markets. CEO Dan Siler continues to lead. (Link)
  10. Harbor Health has agreed to acquire 27 Village Medical clinics in the Houston area. The sites are primary-care offices spread across Harris, Montgomery, Fort Bend and Brazoria counties. They had been run as part of a larger clinic network. The buyer is a Texas primary-care and insurance company that already pairs offices with its own plans in Austin, Dallas, San Antonio and El Paso. This is the fifth market on that model. It bought 32 clinics from the same seller in those other cities in 2025. Plans carry no deductible, and referred specialty care is covered at no cost when one of its clinicians makes the referral. Individual and family enrollment for the new market opens November 1, with coverage effective January 1. No price was disclosed, and the release does not break out patient volume or revenue for the sites. (Link)
  11. Bambu Capital-owned Lemonaid Health has acquired the fitness and longevity business of Dr. B, the telehealth company founded by Zocdoc founder Cyrus Massoumi. Lemonaid Health, the digital pharmacy and telehealth platform owned by Bambu Capital, bought Dr. B’s fitness and longevity business on October 5, 2026, including its national fitness-brand partnerships and longevity membership base; terms were not disclosed. Dr. B built an early scaled gym-as-clinic model in which members can use pre-tax HSA/FSA dollars for gym memberships through letters of medical necessity. The deal gives Lemonaid a gym partner network reaching more than 5 million members and a metabolic-health patient base. Bambu Managing Partner Dylan Runne said it fits the thesis behind Bambu’s Lemonaid purchase: pairing a licensed clinical and pharmacy engine with partners that own the customer relationship. (Link)
  12. Varsity Healthcare Partners-backed United Aesthetics Alliance has acquired St. Louis-based Parkcrest Plastic Surgery and the Aesthetics Center. United Aesthetics Alliance, a physician practice management holding company sponsored by lower middle-market healthcare private equity firm Varsity Healthcare Partners since 2023, completed the acquisition, reported on October 7, 2026; terms were not disclosed. Founded in 2001, Parkcrest provides plastic surgery and medical spa services and is led by co-founding board-certified plastic surgeons Dr. David Caplin and Dr. Patricia McGuire. The deal is the platform’s first acquisition of 2026 and establishes its footprint in Missouri, in line with its strategy of consolidating market-leading plastic surgery practices and affiliated medical aesthetic providers. Parkcrest will keep operating from its current St. Louis location under its existing brand. (Link)
  13. GreyLion Capital-backed Trifecta Collective has acquired the Medical Spa Show from the American Med Spa Association (AmSpa) and entered a long-term partnership with the association. Trifecta Collective, a multi-sector trade show organizer founded in 2021 by industry veteran Rick McConnell and supported by financial partner GreyLion Capital, announced the acquisition on October 6, 2026; terms were not disclosed. Launched by AmSpa in 2018, the Medical Spa Show has drawn nearly 10,000 attendees from more than 5,200 practices and hosted over 750 exhibiting brands; its 10th edition at Wynn Las Vegas in April 2027 is expected to attract more than 3,500 medical aesthetics professionals. McConnell called medical aesthetics one of the fastest-growing segments in healthcare and wellness. AmSpa stays involved under the partnership, and the current show team remains. (Link)
  14. 1 Natural Way, based in Maumee, Ohio, has acquired New England Surgical. The buyer was started in 2014 by Ryan Wright to ship insurance-covered breast pumps and related maternal products. It now works with major carriers in all 50 states, carries pumps from more than a dozen manufacturers, and runs an in-house program with certified lactation consultants. The target, in Fall River, Massachusetts, has sold medical supplies and home equipment across Massachusetts and Rhode Island for more than four decades. What is being bought is the regional payor contracts, not a new product line. Those contracts cover insured patients the Ohio company could not previously bill. The buyer said the add-on widens the set of mothers it can serve at little or no out-of-pocket cost. No price was disclosed. (Link)
  15. RiverGlade Capital has formed Sentinel Care Group, a healthcare franchise platform led by former Right at Home CEO Brian Petranick. Chicago-based RiverGlade Capital, a private equity firm founded in 2017 that makes control and select minority investments in lower middle-market healthcare companies, launched Sentinel Care Group on October 8, 2026. According to PE Hub, the platform will acquire and partner with existing businesses and emerging franchisors, and develop new franchise concepts from scratch. Petranick spent more than two decades at Right at Home, helping grow it from a single Omaha location into an international in-home care franchise with more than 650 territories, and served as president and CEO until 2022. RiverGlade’s franchise experience includes home care franchisor Home Helpers Home Care, acquired in 2021. Capital commitments were not disclosed. (Link)
  16. Emergence, the permanent-capital enterprise backed by The Pritzker Organization, has acquired Charlotte, North Carolina-based patient-reported outcomes software company Clinect Healthcare. Emergence, which provides long-term capital and operating support to software and technology-enabled businesses rather than following a hold-and-exit model, announced the acquisition of Clinect Healthcare on October 8, 2026; terms were not disclosed. Founded in 2012 by CEO Brian Schmitz, Clinect runs an Outcomes Intelligence Platform combining digital intake, patient-reported outcomes, patient experience and reputation management tools, with more than 600 validated outcome measures integrated into practice management and EHR systems. Emergence Operating Partner David Henriksen cited the opportunity as payers demand proof of care results. The deal adds to Emergence’s healthcare software roster after its November 2025 purchase of MedEvolve, and funds data science, AI and interoperability investment. (Link)
  17. Sienna Senior Living (TSX: SIA) has agreed to acquire Brighton Retirement & Active Living, a 165-suite seniors’ residence in Brighton, Ontario, for approximately C$73.8 million. Sienna Senior Living (SIA), the Markham, Ontario-based seniors’ housing owner and operator, signed an agreement on October 8, 2026 to buy Brighton Retirement & Active Living, about 150 km east of Toronto, for a gross price of roughly C$73.8 million, or C$447,000 per suite. Terms add C$1.5 million of income support for the lease-up of the seniors’ apartments and commercial units, plus a C$5.0 million earnout tied to financial targets. The property has 124 retirement suites opened in 2024 and about 95% occupied, 41 seniors’ apartments opened in 2025 and five commercial units. Sienna is funding the deal from cash and credit facilities, with closing expected in Q4 2026. (Link)
  18. Grovecourt Capital-backed Guide Architecture has acquired medical equipment planning firm MAIA as an add-on to its Dallas-based healthcare design platform. West Palm Beach, Florida-based Grovecourt Capital, a lower middle-market investor in founder-led business services and healthcare services companies, added MAIA to portfolio company Guide Architecture in a deal reported on October 8, 2026; terms were not disclosed. MAIA is a 25-person healthcare consulting firm providing medical equipment planning, procurement support, BIM and Revit services, inventory assessment and implementation support. Guide, founded in Dallas in 2014, plans and designs hospitals, outpatient centers, behavioral health facilities and medical office buildings for health systems nationwide. Grovecourt invested in Guide in April 2026, with existing leadership remaining significant owners, and set out a strategy of acquisitions that deepen healthcare expertise and client relationships. (Link)
  19. Oak Hill Capital-backed Petauri has acquired health economics and market access consultancy Franklin Pharmaceutical Consulting. Nashville-based Petauri, the life sciences commercialization platform Oak Hill Capital founded with CEO Dan Renick, announced the acquisition of Franklin Pharmaceutical Consulting (FPC) on October 8, 2026; terms were not disclosed. Oak Hill is committing more than $250 million of equity to Petauri from its latest fund, OHCP VI, and the platform has previously bought The Kinetix Group, the FORCE Communications agencies, Mtech Access, Delta Hat, the Brightly Network agencies, Formulary Insights and Artia Solutions. FPC provides health economics and outcomes research, real-world evidence strategy, payer value communications and dossiers. It folds into Petauri Evidence, with founder Meg Franklin becoming President of Petauri Evidence US. (Link)
  20. Lee Equity Partners-backed Marwood Group has acquired Ronan Healthcare Compliance, expanding its compliance advisory capabilities. New York-based Marwood Group, a healthcare advisory and consulting firm that recently took a strategic investment from Lee Equity Partners, acquired Ronan Healthcare Compliance in a deal announced October 12, 2026. Ronan, founded by Ross and Susan Ronan, provides outsourced compliance officer services, risk assessments, buy-side and sell-side diligence, and program development to more than 60 healthcare organizations across 21 specialties. The full Ronan team joins Marwood, with Ross Ronan becoming Managing Director and Head of Compliance Services. Terms were not disclosed. Bailey & Co advised Ronan. (Link)

Venture Deals and Other

  1. Andreessen Horowitz has led a $120 million Series B in San Francisco-based General Medicine, joined by Matrix, VXI Capital, Eli Lilly (NYSE: LLY), BoxGroup and Ohio-based Mercy Health through Granger Management. a16z General Partner Vineeta Agarwala led the round, announced on October 6, 2026, which lifts General Medicine’s total funding to $152 million. Eli Lilly (LLY) and Cincinnati, Ohio-based Mercy Health, investing through Granger Management, join as strategic backers alongside Matrix, VXI Capital and BoxGroup. Founded in 2023 and launched nationwide in May 2025, General Medicine runs a healthcare store listing more than 2,900 medications, labs, telehealth visits, specialist e-consults and procedures with upfront insurance and cash prices. It has signed up hundreds of thousands of customers with an average NPS of 80. Former Matrix General Partner TJ Parker became full-time CEO in October. Proceeds expand the store into new care categories. (Link)
  2. Dr. Patrick Soon-Shiong’s NantWorks has led a $75 million Series B in San Francisco-based Multiply Labs, joined by AstraZeneca (NASD: AZN), Lingotto, Teradyne (NASD: TER), Strange Ventures, Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. NantWorks led the round, announced on October 6, 2026, which takes Multiply Labs’ total funding above $100 million since its 2016 founding; valuation was not disclosed. New investors AstraZeneca (AZN), Lingotto, Teradyne (TER) and Strange Ventures joined returning backers Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. AstraZeneca is also a customer, underscoring the strategic weight of the cap table. Multiply Labs builds robotic clusters that automate manual steps in biologics manufacturing, initially for cell and gene therapies and now antibodies, viral vectors and mRNA, with systems owned and run in-house by drugmakers. Proceeds fund manufacturing capacity, product development and engineering, regulatory and commercial hiring. (Link)
  3. Sequoia Capital, First Round Capital and Hummingbird Ventures have backed clinical AI company Healthleap in $38 million of combined seed and Series A funding. Healthleap disclosed the $38 million on October 8, 2026, with Sequoia partner Alfred Lin and First Round co-founder Josh Kopelman both endorsing the investment. Founded in 2022 by siblings Josiah and Jemima Meyer, the company continuously analyzes patient records, including notes, labs, vitals and orders, to flag undiagnosed conditions and push risk scores into EHR workflows. It started with disease-related malnutrition, which costs the U.S. system up to $58 billion annually; one Penn Medicine hospital attributed $23.8 million a year in reimbursement and length-of-stay benefits to the platform. Proceeds fund expansion to more than 40 conditions and hiring to reach hundreds of hospitals. (Link)
  4. The Florida Opportunity Fund and Tampa General Hospital’s TGH Ventures have co-led a $35 million growth equity investment in Spark Pediatrics, with Town Hall Ventures, UPMC Enterprises and Memorial Hermann participating. Spark Pediatrics, which operates Prescribed Pediatric Extended Care centers for children with medical complexities, including a Clearwater, Florida location, announced the $35 million equity investment on October 9, 2026. The Florida Opportunity Fund and TGH Ventures led, with continued participation from existing investor Town Hall Ventures and all of Spark’s existing strategic partners, including UPMC Enterprises and Memorial Hermann. The health system backers give Spark strategic relationships across Florida, Pennsylvania and Texas. Proceeds will support Spark’s leading presence in Florida, growth in Texas and expansion into Pennsylvania, Louisiana and other new states. Valuation and round designation were not disclosed. (Link)
  5. Oak HC/FT has led a $31 million Series A in San Francisco-based Vitalize, joined by Norwest, .406 Ventures, Constellation Ventures, Y Combinator, Rock Health Capital and MemorialCare Innovation Fund. Oak HC/FT partner Vig Chandramouli led the round, announced on October 6, 2026, with health system venture arm MemorialCare Innovation Fund participating as a strategic investor. Vitalize sells an AI-native platform that automates scheduling and forecasts demand to coordinate staffing and bed capacity across health systems, integrating with EMR and time-and-payroll systems. It manages millions of shifts a week across dozens of enterprise health systems; St. Luke’s Health reported a 54% cut in premium labor spend within 12 weeks. Oak HC/FT, with more than $7 billion under management, views hospital labor, a nearly $1 trillion cost line, as an underpenetrated software market. Proceeds fund growth, deployment and throughput AI. (Link)
  6. Maveron has led a $25 million Series A in New York-based oral care membership company Wally, joined by Bling Capital and angel investors including Hims & Hers Health (NYSE: HIMS) co-founder Jack Abraham. Maveron partner Jason Stoffer backed Wally’s model of replacing insurance-driven dentistry with a $249 annual membership covering unlimited cleanings, AI-supported diagnostics, exams and whitening; the round was announced on October 7, 2026. Bling Capital and angels including Jack Abraham participated. Wally has passed 50,000 members who visit three times a year, reports a 97% hygienist retention rate and operates 15 locations in co-working spaces across New York City, Philadelphia, Jersey City and Chicago. It also announced a strategic partnership with EMS Dental. Proceeds fund expansion from 15 to 100 locations by end-2027, including Washington DC, Atlanta, Austin and Miami. (Link)
  7. F-Prime has led a $20 million Series A in Allentown, Pennsylvania-based AblePay Health, with participation from A1 Health Ventures and .406 Ventures. F-Prime principal Nikhil Marathe led the round, announced on October 7, 2026, as AblePay enters its second decade. Chicago-based A1 Health Ventures, whose limited partners are health systems operating more than 110 hospitals, and Boston’s .406 Ventures, with over $1.3 billion under management, joined. Founded in 2016, AblePay integrates with providers to guarantee non-recourse payment on an accelerated timeline while offering enrolled patients flexible payment options, savings on out-of-pocket costs and free billing advocacy. The company cites $591 billion of U.S. out-of-pocket healthcare spending in 2025, up 6%. Proceeds will expand its reach to more health systems and deepen its technology platform. (Link)
  8. Norrsken VC has led a $20 million Series A in Paris- and New York-based AI medical receptionist company Vocca, joined by Heal Capital, Speedinvest and firstminute capital. The round, announced on October 6, 2026, lifts Vocca’s total funding to $25 million about a year after its previous raise; valuation was not disclosed. Founded in July 2024 by Eliott Hoffenberg and Hugo Danet, Vocca builds specialty-specific AI agents that answer patient calls, book and reschedule appointments and handle routine requests for medical practices. It has grown from 2,000 to 15,000 practitioners in a year across the U.S. and Europe and now handles more than one million patient conversations a month. Proceeds will deepen its U.S. presence through its New York office, add specialties and channels beyond voice, and fund about 40 hires. (Link)
  9. NFX has led a $7 million seed round in Altro Health, with Founder Collective and Primetime Partners’ Abby Miller Levy participating. NFX general partner James Currier said the firm backed Altro, formerly Lyv Health, for its position in a large new consumer category with no clear leader; the round was announced on October 6, 2026. Altro operates a Shopify-style platform that lets personal trainers, gyms and medspas offer clinician-prescribed peptides, GLP-1s, hormone therapy and lab testing under their own brands, with a board-certified clinical team supervising each service and products sourced from licensed 503A and 503B pharmacies. More than 500 businesses already use the platform, with plans starting at $319 a month. Proceeds fund product development, hiring, and sales and marketing. (Link)
  10. Listen Ventures, Cake Ventures, LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures have backed New York-based deprescribing platform Outro in $7 million of pre-seed and seed funding. Outro disclosed the $7 million across pre-seed and seed rounds on October 8, 2026, with participation from Listen Ventures, Cake Ventures, Jason Calacanis’ LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures, among others. Co-founded by CEO Brandon Goode and psychiatric deprescribing researcher Dr. Mark Horowitz, Outro runs a virtual clinic that helps patients taper off antidepressants through personalized plans, monitoring and clinician support, and is available in 14 states. It cites roughly 50 million Americans taking antidepressants. Proceeds expand the clinician network, apply AI to tapering workflows and extend the model into other medication classes. (Link)

Market Rumors / IPO

  1. Solventum (NYSE: SOLV) is seeking bids for its Health Information Systems unit, pitched at a $5.5 billion to $7 billion valuation. Solventum, the medical products and technology company spun out of 3M, is collecting initial bids for its Health Information Systems division, according to reports on October 12, 2026. The unit provides hospitals and health systems with medical coding, billing, documentation and revenue cycle management software and generated about $1.4 billion of sales last year. Solventum announced plans to separate the business in August 2026 as it focuses on medsurg and dental. Shares slipped after the report. No buyer has been named, and a sale or spin remains possible. (Link)
  2. Bambusa Therapeutics has filed a Form S-1 for a proposed Nasdaq IPO under the symbol B BTX.Bambusa was incorporated in Boston in March 2024. It is a clinical-stage company working on long-acting bispecific antibodies for immunology and inflammation. BBT001 targets IL-4Rα and IL-31 for atopic dermatitis and chronic spontaneous urticaria. BBT002 targets IL-4Rα and IL-5 for COPD, nasal polyps and asthma. Two earlier programs are still preclinical. Private investors including RA Capital, BVF Partners, ATHOS and Dawn Biopharma have put in about $136 million. Cash was $71.5 million at June 30. The filing does not set a share count or a price. Named underwriters include BofA Securities, Evercore, UBS and Cantor. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 14th, 2026

LECO_Weekly-Healthcare-News_9-14-2026Download

Healthcare Weekly News and Deals –Sept 14th, 2026

  1. Addus HomeCare (NASD: ADUS) to Acquire Advent International–Backed AccentCare’s Personal Care Division for Approximately $275 Million Advent International’s AccentCare is selling only the non-New York personal-care book; hospice and skilled home health stay with the seller. Addus, a scaled non-franchise home-care operator listed on Nasdaq, is paying about $275 million after customary adjustments and funding the check with revolver and cash. The assets serve roughly 13,700 patients a day across 10 states and should add about $280 million of annualized personal-care revenue, a 19% lift to Addus’s base. Density is heaviest in Texas, Illinois, California and Arizona, with additional volume in Colorado, Georgia, Minnesota, Pennsylvania, Tennessee and Washington. The purchase extends Addus’s Medicaid-heavy personal-care footprint rather than buying hospice or Medicare home health.  (Link)
  2. Axogen (NASD: AXGN) to Acquire BioCircuit Technologies for $200 Million in Cash Axogen is paying $200 million cash for BioCircuit, with $1 million held back for the post-close true-up, and is funding the check with a concurrent $208.7 million common-stock offering. The prize is NerveTape, the first FDA-cleared sutureless device for peripheral nerve repair, plus ConformaWrap. BioCircuit did about $11 million of revenue in 2025 and is running at roughly $24 million on more than 14,000 implants across 400-plus hospital and ASC accounts. Convertible notes convert and an unrelated electronics R&D unit is spun out before closing. Management expects year-one accretion to growth, adjusted EBITDA margin and adjusted EPS while remaining free-cash-flow positive.  (Link)
  3. COSCIENS Biopharma (TSX: CSCI) Acquires Nualtis from AtaiBeckley (NASD: ATAI) for $15 Million Plus Earnouts COSCIENS is buying Montreal oral-thin-film CDMO Nualtis, formerly IntelGenx, from AtaiBeckley for $15 million plus four earnouts equal to 10% of adjusted EBITDA in 2027–2030. Nine million dollars was paid at close; $6 million is deferred six months. The plant is FDA- and Health Canada-inspected and runs VersaFilm for human therapeutics and VetaFilm for veterinary use, with an existing pipeline and pharma partnerships. A concurrent first tranche of unsecured convertibles raised about $6 million toward a $20 million cap and funded the closing check. For a small TSX-listed ingredients company, the deal is a way to own a purpose-built film platform rather than build one.  (Link)
  4. Patient Square–Backed Hanger to Acquire AEA’s Numotion; Combined Company to Be Called Hanger Numotion Patient Square is putting two mobility platforms under one roof in a cash purchase. Hanger contributes 925 U.S. orthotic and prosthetic clinics; AEA Investors’ Numotion contributes more than 200 complex-rehab and mobility sites in the United States and Canada. Combined they will serve more than 1.5 million patients a year and keep both brands and clinical operations. Numotion CEO Mike Swinford, in the seat since 2014 after two decades at GE including GE Healthcare Services, will run the combined company as Hanger Numotion; Pete Stoy steps aside. The combination is PE-backed specialty-provider consolidation across complementary mobility verticals, not a single-clinic tuck-in.  (Link)
  5. Apple (NASD: AAPL) Acquires Berkeley Brain-Sensing Startup Sonera Apple has bought Sonera, a Berkeley company that builds chip-scale magnetic sensors to read neural and muscle activity without implants or skin-contact electrodes. Co-founders Nishita Deka and Dominic Labanowski started the firm in 2018 out of UC Berkeley; it later raised about $20 million, including an $11 million 2023 seed, and marketed an S1 biomagnetic chip for muscle sensing, prosthetics and wearables. Magnetic readout is meant to avoid the skull-dampening that limits electrical EEG. Apple has not said what the team will work on. Outside write-ups point at Watch-class neuromuscular monitoring and hands-free accessibility; those uses are inferred, not confirmed. (Link)
  6. Labcorp (NYSE: LH) Acquires Great Point Partners’ MLM Medical Labs Great Point Partners is exiting MLM Medical Labs, the central- and specialty-lab it built in the United States, Germany and South Africa. Labcorp is folding the network in so it owns laboratories on four continents — North America, Europe, Asia and Africa — including the first CAP-accredited central lab on the African continent. MLM adds biomarker and specialty capacity for multinational trial work that Labcorp previously covered through a mix of owned sites and partners. The industrial logic is one operator, one scientific and regulatory stack, on global protocols rather than a patchwork of affiliate labs.  (Link)
  7. General Catalyst– and CVS Health Ventures–Backed H1 Acquires Defacto Health to Add Provider-Network Intelligence H1, the physician-data platform backed by General Catalyst and more recently CVS Health Ventures, is buying Defacto Health, a specialist in payer-network and directory intelligence. Defacto maps which clinicians sit in which networks and which plans they accept — the data health plans use to test directory accuracy, isolate error clusters and benchmark access. It was already a data partner. Co-founders Ron Urwongse and Tarun J. Theogaraj, both formerly of CAQH, join H1 and will keep running the product inside the Doctor Graph rather than as a standalone brand. The buy sits against ongoing CMS and plan pressure on directory accuracy as provider and network data change continuously.  (Link)
  8. Eir Partners Acquires Accumulus Technologies, the Life-Sciences Regulatory Cloud Platform Eir Partners is buying Accumulus Technologies, a San Francisco regulatory-cloud platform that connects more than 75 agencies to life-sciences sponsors. The product is built for multi-agency review rather than point-to-point filings and already has live Veeva RIM connectivity. Accumulus was spun out of nonprofit Accumulus Synergy in 2025 so it could raise capital and sell commercially; CEO Francisco Nogueira stays. Eir, a healthcare software firm, is treating the asset as a category platform at the intersection of life sciences, technology and global regulation rather than a point tool for a single agency workflow.  (Link)
  9. 1315 Capital Buys Argonaut’s Life Sciences and Diagnostics Unit; Business Relaunches as Aluris Sciences 1315 Capital is buying only Argonaut’s life-sciences and diagnostics manufacturing unit and relaunching it as Aluris Sciences. Telegraph Hill Partners, New Vale Capital and management keep the Carlsbad aseptic fill-finish CDMO. Aluris runs formulation through commercial production for diagnostics, life-sciences and combination-product customers and will operate independently; staff and resources were already largely separate, so live programs do not move. Sale proceeds recycle into Argonaut’s fill-finish capacity. The structure is a clean carve-out rather than a whole-company sale of a dual-vertical CDMO.  (Link)
  10. SK Capital–Backed Precera Medical Acquires Additive Metal Services Precera Medical, the four-plant orthopedic and interventional OEM SK Capital carved out of LISI Medical in November 2025, is adding Additive Metal Services of Port Huron. The shop brings metal-injection molding and sinter-based additive manufacturing for precision components — robotic-surgery end effectors and distal interventional-catheter parts among the named uses. Precera already runs design, prototyping, precision machining, micro-feature work, automation and finished-device assembly across Minnesota and France. Customer programs and tooling stay. The add-on is process-capability adjacency on a new platform, not a new end-market.  (Link)
  11. Avesi Partners–Backed Danforth Health Acquires Ambit RD Avesi Partners’ Danforth Health is buying Ambit RD, a rare- and specialty-disease shop that sells commercial strategy, advanced analytics and AI-assisted patient identification into biopharma. CEO Rob Sederman and CCO Ned Kitfield stay. Ambit is the latest add onto a platform that has already rolled up Asymmetry Group, PharmaDirections, VPMR, Advyzom, Benchworks, Elite BioPharma Consulting and Argot Partners. The thesis is a single commercialization backbone from clinic through launch rather than another standalone consultancy sitting beside the last one. Rare-disease commercial work is one of the few remaining fee pools that still pays for specialist analytics.  (Link)
  12. RiverGlade Capital Makes Platform Investment in Senior Living Residences RiverGlade Capital is backing Senior Living Residences, the Braintree operator of 24 independent living, assisted living and memory-support communities across New England and the broader Northeast. Founder Robert Larkin and CEO Tadd Clelland stay; the SLR name stays. The company has run service-enriched buildings for nearly four decades and includes the Compass Memory Support Neighborhoods line. RiverGlade is a healthcare PE firm that typically partners with founder-led lower-middle-market operators and funds people, operations and both organic and acquired growth. No price was printed. The check is meant to keep expanding the Northeast book without changing the operating identity. The transaction closed in July; this is the first public write-up.  (Link)
  13. Latticework Capital–Backed Beacon Behavioral Partners Acquires Albaron’s Prime Psychiatry Latticework Capital’s Beacon Behavioral Partners is buying Prime Psychiatry from Albaron Partners, which backed founder Dr. Efosa Airuehia in 2022. Prime is outpatient and interventional psychiatry — medication management plus TMS and Spravato — for children, adolescents and adults across Dallas–Fort Worth and Austin. The clinics join a national behavioral platform that has been adding partner practices across the Southeast and Midwest while leaving local brands intact. Local physicians stay. The sale is a sponsor-to-sponsor handoff of a regional interventional-psychiatry density play rather than a de novo clinic build.  (Link)
  14. Santé Ventures–Backed Jaguar LAA Acquires Johnson & Johnson (NYSE: JNJ) Laminar Program Assets Santé Ventures formed Jaguar LAA with members of the Laminar team to take Johnson & Johnson’s left-atrial-appendage program out of a strategic and finish development as an independent company. The asset is a catheter-based LAA-closure approach aimed at stroke-risk reduction in non-valvular atrial fibrillation and designed to leave minimal hardware in the left atrium. Key program assets and the originating engineers move together. The structure is a classic medtech carve-out plus NewCo financing rather than a license back to the seller.  (Link)
  15. InTandem-Backed Ivy Fertility Acquires Santa Barbara Fertility Center InTandem Capital’s Ivy Fertility is adding Santa Barbara Fertility Center, opened in 2008 by reproductive endocrinologist Rene Allen after a USC fellowship. Allen stays and continues to practice. The same announcement adds five other physicians across Ivy’s network and a build-out in male fertility. Local brand is retained. Ivy is already a multi-state IVF platform; Santa Barbara is a coastal California density add with an existing physician and lab book, not a 100%-owner partnership that leaves control unchanged.  (Link)
  16. LongueVue-Backed Summit / Pinnacle Acquires Dallas Research Institute LongueVue Capital’s Summit / Pinnacle site network is buying Dallas Research Institute, a single-site DFW unit opened in 2024 with the late hepatologist Dr. Stephen Harrison and focused on MASLD, MASH and obesity trials. Principal investigator Dr. Pedro Castillo Jr. stays. The buyer already runs 15 owned U.S. sites plus 110-plus partner sites in eight countries, with IRO, recruitment, medical-communications and early-phase CRO affiliates under the same roof. The add is metabolic-site density in a high-enrolling metro rather than a new therapeutic vertical.  (Link)
  17. VSS-Backed Olympus Cosmetic Group Acquires Gallaher Plastic Surgery & Med Spa VSS-backed Olympus Cosmetic Group is buying Gallaher Plastic Surgery & Med Spa, its first Tennessee practice and the entry into Knoxville. Dr. Tom Gallaher stays under a physician-led model and the local brand is being kept. Olympus is a surgeon-founded aesthetics platform assembling plastics and med-spa density market by market rather than a roll-up that rebrands every site on day one. The add-on is a local-brand-preserved clinic purchase into an unpenetrated MSA, not a new platform launch.  (Link)
  18. Frazier-Backed LUX Infusion Acquires Two Northeast Ambulatory Infusion Centers Frazier Healthcare’s LUX Infusion is buying two Northeast ambulatory infusion centers: South Jersey Pediatric and Adult Infusion Center in Cherry Hill, N.J., and Northeast Infusion Therapy in Latham, N.Y. The purchases are separate from the August Infuse IQ deal. LUX is a clinician-led home-plus-center platform after the BioMatrix rebrand. The two sites bring chair capacity and existing physician-referral books in two new Northeast MSAs, which is the density the platform needs if home infusion and AIC are going to sit on the same operating system.  (Link)
  19. Altas Partners and L Catterton Agree to Acquire Fullscript from HGGC Altas Partners and L Catterton are buying a majority stake in Fullscript from HGGC and Snapdragon Capital Partners. The Ottawa platform, founded in 2011, sells practitioners an integrated stack of diagnostics, treatment planning and dispensed supplements and already cites more than 135,000 clinicians, about 10 million patients a year and $1 billion-plus of revenue. HGGC and Snapdragon put $240 million in during 2021, later added Rupa Health for labs, and used a Leonard Green continuation vehicle in 2025. The new sponsors are taking majority control to fund further clinical-tool and North American expansion.  (Link)
  20. Revvity (NYSE: RVTY) to Acquire France’s Human Cell Design Revvity is buying Human Cell Design, a French specialist in human pancreatic beta-cell models. The flagship line is EndoC-βH5, sold with specialized media, reagents, preclinical services and the NatLine cell-line platform for diabetes, obesity and other metabolic work, including GLP-1 and GPCR programs. Revvity is treating the company as a reagents tuck-in that sits next to HTRF, AlphaLISA, ATPlite and high-content screening rather than a new instruments franchise. Human-relevant cell models have become a procurement item for metabolic and incretin discovery groups that want to reduce animal-only screening.  (Link)
  21. Novo Holdings Makes Minority Investment in China’s ForYou Medical; GL Capital Remains Majority Novo Holdings is taking a minority stake in ForYou Medical; GL Capital remains majority owner. The Huizhou company is a CDMO focused on advanced wound-care manufacturing for global device customers rather than a branded finished-goods play. Novo Holdings’ China head framed the check as the firm’s first China medtech ticket and part of a larger Asia ramp in both check size and local team. The industrial logic is specialized converting capacity plus China-to-global customer access, not a control deal or a domestic hospital chain.  (Link)
  22. Nvidia- and Health System–Backed Artisight Acquires TMG Global Artisight, the Nvidia- and health-system-backed smart-hospital vendor, is buying TMG Global, a healthcare infrastructure and site-readiness shop that runs large technology deployments. The team comes in-house so health systems have one accountable path from clinical-space and MDF/IDF surveys through hardware staging, install, validation, training and Day-1 support. Artisight’s platform uses computer vision and ambient sensing to run operating rooms and inpatient units; the bottleneck has been deployment, not the model. The purchase is operational capacity for enterprise rollouts, not a new clinical product.  (Link)
  23. Sanofi (NASD: SNY) and Braun Family–Owned Cheplapharm to Form Mature-Medicines Partnership Sanofi is moving a tail of 20 mature medicines and three plants to Cheplapharm, the German family-owned established-products company controlled by the Braun family, and taking a 26.4% equity stake in return. The plants are Csanyikvölgy in Hungary (about 400 employees), Jurong in Singapore (about 100) and Ploërmel in France (about 65), and they include manufacturing for Lovenox/Clexane. The two sides have collaborated since 2014. Commercial transfer is planned to start in early 2027, then the sites, subject to works-council consultation and regulatory approvals. Structure is a partnership and minority stake, not a signed control sale of Cheplapharm.  (Link)

Venture Deals and Other

  1. Forus Raises $150 Million Series C at a $3 Billion Valuation, Led by Bain Capital Ventures Bain Capital Ventures led a $150 million Series C in Forus at a $3 billion valuation, four months after a $160 million Series B. Every existing institution re-upped, including Thrive, General Catalyst, Accel, Redpoint, BoxGroup and Pear; cumulative capital now exceeds $300 million. Forus, formerly Tandem, builds an AI agent per prescription that sits between the physician, payer, pharmacy and manufacturer to clear access work and is free to doctors and patients. Coverage is all 50 states and about 85% of U.S. residential ZIP codes. Proceeds go to specialty expansion, more agents and commercial headcount.  (Link)
  2. BrainChild Bio Closes $116 Million Series A BrainChild Bio raised $116 million in a Series A led by a family fund and foundation aligned with the pediatric-oncology mission; Seattle Children’s, the original investor, and WRF Capital joined. Proceeds fund ILLUMINATE, the Phase 2 pivotal trial of BCB-276, a B7-H3 CAR-T, in diffuse intrinsic pontine glioma, and push triple-target construct BCB-214 toward first-in-human glioblastoma work. The platform is licensed from Seattle Children’s. Steven Brugger is CEO. DIPG remains a category with almost no approved options, which is why a mission-aligned family check can lead a round of this size.  (Link)
  3. TwoStep Therapeutics Raises Oversubscribed $62.5 Million Series A; FDA Clears TS-104 IND Insight Partners and Medical Excellence Capital led an oversubscribed $62.5 million Series A in TwoStep Therapeutics; Pfizer Ventures and Merck KGaA’s M Ventures co-led, with NFX, 2048 Ventures and Stanford joining. Cumulative capital is $71.2 million. The company’s peptide-drug conjugate binds five tumor-associated integrins rather than a single antigen, a design aimed at tumors that lack a clean one-target profile. FDA has cleared the TS-104 IND; Phase 1 enrollment is expected later this year. Proceeds also fund a radioligand program and next-generation peptide conjugates.  (Link)
  4. Kura Oncology (NASD: KURA) Launches Caspian Therapeutics with $50 Million Series A Led by BVF; Eli Lilly (NYSE: LLY) Participates Kura Oncology launched Caspian Therapeutics with a $50 million Series A led by BVF Partners. Kura contributed menin-inhibitor IP including KO-7246, invested $4.3 million and keeps about 49%. Eli Lilly and the T1D Fund joined, alongside Invus, Montanova and Kura management. Proceeds take KO-7246 into Type 1 and Type 2 diabetes proof-of-concept and fund a second menin asset for broader cardiometabolic use; oncology stays at the parent. Kura CEO Troy Wilson is executive chair; Rob Spencer is president and COO. Phase 1 is targeted by the end of 2027.  (Link)
  5. Implicity Raises $40 Million Growth Round Led by IRIS and Five Arrows IRIS and Rothschild & Co’s Five Arrows led a $40 million growth round in Implicity. The Cambridge and Paris company already covers more than 250 medical centers and monitors 120,000-plus patients a day across the United States, France and Germany. The platform is FDA-cleared AI sitting on connected pacemakers, defibrillators and implantable loop recorders; published real-world data cite a 26% mortality reduction and a 4% drop in hospitalizations versus conventional remote monitoring. Proceeds go to U.S. commercial hiring, U.S.-specific product work and further AI, including heart-failure prediction.  (Link)
  6. Epsilon Health Emerges from Stealth with $27.6 Million Led by AlleyCorp AlleyCorp led a $27.6 million stealth round in Epsilon Health; Uncork Capital, Renegade Partners, SemperVirens and Jack Altman joined. Epsilon is an AI-native radiology practice — physicians plus models — not a point-solution vendor selling into someone else’s group. It already serves more than 250,000 patients, reads 2,500-plus studies a day, and handles more than half the volume at one large outpatient imaging chain. Management says it is on track for about 1% of daily U.S. X-rays this year. Head of machine learning is ex-DeepMind; the CMO is former Envision Radiology CMO.  (Link)
  7. GenHealth.ai Raises $16.5 Million Series A Led by Flare Capital Partners Flare Capital Partners led a $16.5 million Series A in GenHealth.ai. Craft Ventures and Obvious Ventures re-upped; Eniac, InHealth Ventures, Epsilon Health Investors and ARTIS came in. Cumulative capital is about $30 million after a 2023 seed. The Boston company, spun out of 1upHealth, deploys agents inside existing EHRs and payer systems for intake, eligibility, prior authorization, billing, denials and appeals rather than selling another system of record. Management cites a 34% revenue lift and up to 80% admin-cost reduction; Guidehealth reports 4x productivity on intake and prior auth.  (Link)
  8. UrgentIQ Raises $15 Million Series A Led by Five Elms Capital Five Elms Capital, a vertical-software growth shop with more than $3 billion under management, led a $15 million Series A in UrgentIQ. The product is an AI-native EMR and operating system built for urgent care rather than a hospital or primary-care fork. Proceeds fund a native billing module, AI documentation and coding, live insurance verification and an AI checkout agent, plus commercial headcount. Founder Nat Gibbs is building against a market that still runs on hospital-grade EMRs never designed for high-throughput episodic visits. Earlier seed capital was not a named institutional growth round.  (Link)

CLICK HERE to sign up
for all news and updates